Literature DB >> 2492113

Innovative approaches to plasminogen activator therapy.

E Haber1, T Quertermous, G R Matsueda, M S Runge.   

Abstract

Plasminogen activator therapy for acute myocardial infarction has become standard medical practice. Bleeding complications, however, limit the utility of the currently available agents. This article reviews how the tools of molecular biology and protein engineering are being used to develop safer and more effective plasminogen activators.

Entities:  

Mesh：

Substances：

Year:  1989        PMID： 2492113     DOI： 10.1126/science.2492113

Source DB:  PubMed          Journal:  Science        ISSN： 0036-8075            Impact factor:   47.728


  19 in total

1.  A catalytic switch and the conversion of streptokinase to a fibrin-targeted plasminogen activator.

Authors:  G L Reed; A K Houng; L Liu; B Parhami-Seren; L H Matsueda; S Wang; L Hedstrom
Journal:  Proc Natl Acad Sci U S A       Date:  1999-08-03       Impact factor: 11.205

Review 2.  New thrombolytic strategy: bolus administration of tPA and urokinase-fibrinogen conjugate.

Authors:  A V Maksimenko; E G Tischenko
Journal:  J Thromb Thrombolysis       Date:  1999-06       Impact factor: 2.300

Review 3.  Advances in thrombolytic therapy.

Authors:  M Verstraete
Journal:  Cardiovasc Drugs Ther       Date:  1992-04       Impact factor: 3.727

Review 4.  The second century of the antibody. Molecular perspectives in regulation, pathophysiology, and therapeutic applications.

Authors:  J Braun; A Saxon; R Wall; S L Morrison
Journal:  West J Med       Date:  1992-08

Review 5.  Cardiovascular drugs.

Authors:  P Vermeij
Journal:  Pharm Weekbl Sci       Date:  1992-08-21

Review 6.  Immunoscintigraphy of thrombosis.

Authors:  M N Wasser; E K Pauwels
Journal:  Eur J Nucl Med       Date:  1990

7.  Protein engineering and site-directed mutagenesis. Patents and literature.

Authors:  J S Dordick
Journal:  Appl Biochem Biotechnol       Date:  1990-10       Impact factor: 2.926

8.  A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo.

Authors:  M S Runge; T Quertermous; P J Zavodny; T W Love; C Bode; M Freitag; S Y Shaw; P L Huang; C C Chou; D Mullins
Journal:  Proc Natl Acad Sci U S A       Date:  1991-11-15       Impact factor: 11.205

9.  Gene technology and the drugs of tomorrow.

Authors:  J Drews
Journal:  Pharm Weekbl Sci       Date:  1990-02-23

10.  Synergistic fibrinolysis: combined effects of plasminogen activators and an antibody that inhibits alpha 2-antiplasmin.

Authors:  G L Reed; G R Matsueda; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1990-02       Impact factor: 11.205
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.